title: [Cardiovascular risk factors associated with antiretroviral therapy].
abstract: HIV-infected patients share traditional cardiovascular risk factors with the general population. Moreover, HIV per se significantly increases the risk of cardiovascular disease. Consequently, control of HIV infection with highly-active antiretroviral therapy (HAART) helps to reduce vascular risk in HIV-infected patients. However, there is evidence that HAART increases cardiovascular risk and the use of abacavir, didanosine, lopinavir/ritonavir and indinavir has been associated with the development of acute myocardial infarction (AMI). However, the absolute risk of AMI in patients receiving HAART is very low in relation to the benefit obtained with antiretroviral therapy.
authors.affiliation: Servicio de Medicina Interna, Hospital de Poniente, El Ejido, Almería, España.
authors.forename: Inés
authors.initials: I
authors.lastname: Pérez-Camacho
authors.forename: Angela
authors.initials: A
authors.lastname: Camacho
authors.forename: Julián
authors.initials: J
authors.lastname: Torre-Cisneros
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D001161:Arteriosclerosis / Q000453:epidemiology / Q000209:etiology; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics; D015331:Cohort Studies; D015897:Comorbidity; D004198:Disease Susceptibility; D004730:Endothelium, Vascular / Q000503:physiopathology; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced* / Q000453:epidemiology; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects; D024821:Metabolic Syndrome / Q000150:complications; D009203:Myocardial Infarction / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors